Drug Profile
Paltusotine - Crinetics Pharmaceuticals
Alternative Names: CRN 00808Latest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Crinetics Pharmaceuticals
- Class Amines; Antineoplastics; Antisecretories; Fluorobenzenes; Nitriles; Piperidines; Quinolines; Small molecules
- Mechanism of Action Somatostatin receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acromegaly
- Phase II Malignant carcinoid syndrome; Neuroendocrine tumours
Most Recent Events
- 21 Mar 2024 Adverse events and efficacy data from a phase III PATHFNDR 2 trial in Acromegaly released by Crinetics Pharmaceuticals
- 12 Mar 2024 Crinetics Pharamceuticals plans a phase III trial for Malignant carcinoid syndrome by the end of 2024
- 12 Mar 2024 Updated Efficacy and adverse event data from a phase II trial in Neuroendocrine tumours and carcinoid syndrome released by Crinetics Pharamceuticals